



OPEN

# Lack of association between the *CDH1* polymorphism and gastric cancer susceptibility: a meta-analysis

SUBJECT AREAS:  
GASTRIC CANCER  
CANCER GENETICSBenchun Jiang<sup>1</sup>, Ke Zhu<sup>2</sup>, Hua Shao<sup>1</sup>, Chenhui Bao<sup>1</sup>, Jinlei Ou<sup>1</sup> & Wei Sun<sup>1</sup>Received  
23 September 2014Accepted  
16 December 2014Published  
20 January 2015Correspondence and  
requests for materials  
should be addressed to  
W.S. (sunw@sj-  
hospital.org)<sup>1</sup>Department of General Surgery, Affiliated Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning, China,  
<sup>2</sup>Department of Hematology, Affiliated Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning, China.

E-Cadherin (*CDH1*) plays a key role in cell adhesion, which is vital to the normal development and maintenance of cells. Down regulation of *CDH1*, may lead to dysfunction of the cell-cell adhesion system, resulting in increased susceptibility to tumor development and subsequent tumor cell invasion and metastasis. The *CDH1* C-160A polymorphism could decrease its transcription efficiency and may increase susceptibility to cancer development, but its relevance to gastric cancer is generally disputed. Consequently, we performed a meta-analysis of published case-control studies, including 4218 gastric cancer cases and 5461 controls. Overall, no significant association was observed between the *CDH1* C-160A polymorphism and risk of gastric cancer in all genetic models. In the stratified analysis by total sample size, a significant association was observed in the small sample size subgroup (total sample size < 300), but the results should be interpreted with caution. In conclusion, this meta-analysis failed to confirm the association between the *CDH1* C-160A polymorphism and risk of gastric cancer. Large-scale and well-designed studies are needed to confirm our findings.

Gastric cancer is the second most common cancer worldwide. Although the incidence of gastric cancer has decreased in recent years, it remains a major health concern due to the high mortality and poor prognosis for this disease<sup>1,2</sup>. Although it is well known that environmental factors, dietary habits, tobacco smoking, alcohol consumption, and *Helicobacter pylori* infection are associated with the risk of gastric cancer, host genetic factors may be one of the most critical in gastric carcinogenesis<sup>3–7</sup>.

Cell-cell adhesions play crucial roles not only in regulating morphogenesis of both normal and neoplastic tissues but also in invasion and metastasis of cancer. E-cadherin, the so-called *CDH1*, is a member of a family of transmembrane glycoproteins expressed in epithelial cells and is responsible for calcium-dependent cell-cell adhesion<sup>8–10</sup>. It plays an important role in cell adhesion, which is vital to the normal development and maintenance of cells. Dysfunction of the cell-cell adhesion system triggers neoplastic development. In humans, the *CDH1* gene is located on chromosome 16q22.1, and codifies a mature polypeptide with 728 amino acids<sup>11</sup>. Since *CDH1* is the prime cell adhesion mediator, the gene is thought to serve as a tumor invasion suppressor. Down regulation of *CDH1*, may lead to a loss of *CDH1* mediated cell-cell adhesion, resulting in increased susceptibility to tumor development and subsequent tumor cell invasion and metastasis<sup>12</sup>.

In recent years, studies have confirmed that single-nucleotide polymorphisms (SNPs) in the promoter region of the *CDH1* gene influence its transcriptional activity and alter the expression of E-cadherin. It has been postulated in a series of studies that these SNPs may be associated with cancer development<sup>13–15</sup>. The most widely studied polymorphism is *CDH1* C-160A (rs16260), where the A allele decreases transcription efficiency of the *CDH1* gene and may increase susceptibility to cancer development in some populations. Recently, a considerable number of studies have been conducted to investigate the associations between the *CDH1* C-160A polymorphism and susceptibility of gastric cancer<sup>16–35</sup>. However the results remain controversial and ambiguous. In 2007, Medina-Franco<sup>26</sup> found that the AA genotype had a significantly elevated risks for gastric cancer in a Mexican population (OR = 6.5, 95% CI = 2.1–19.6). In 2010, Al-Moundhri<sup>32</sup> found the similar result in an Omani population (OR = 3.6, 95% CI = 1.1–11.8). In contrast, in 2002, Wu<sup>18</sup> observed that in a Taiwanese population the frequency of the variant AA genotype in gastric cancer cases was significantly lower than that of controls, conferring a 5-fold decrease in the risk of gastric cancer (OR = 0.20, 95% CI = 0.06–0.56) compared with the CC genotype. However, in 2009, Corso<sup>31</sup> reported that the *CDH1* C-160A polymorphism was not significantly



associated with gastric cancer susceptibility in an Italian population (OR = 0.7, 95% CI = 0.3–1.5). Meta-analysis is considered a powerful tool for summarizing the contradicting results from different studies with more statistical power. To solve the problem of inadequate statistical power and controversial results, we performed a meta-analysis of published case-control studies.

## Results

**Characteristics of eligible studies.** The literature search for this meta-analysis started in March 2014 and ended in August 2014. A total of 116 relevant articles were yielded by the literature search. After screening the titles, 78 articles were excluded because of obvious irrelevance. After reading the abstracts and full texts of the remaining articles, review articles ( $n = 12$ ) as well as articles without controls ( $n = 4$ ) and sufficient data ( $n = 2$ ) were excluded. Thus, a total of 20 articles<sup>16–35</sup> (22 independent case-control studies) met the inclusion criteria, and included 4218 gastric cancer cases and 5461 controls. The data collected from the included studies were summarized in Table 1, and the flow chart of study selection process was shown in Fig. 1.

**Results of meta-analysis.** Overall, no significant association was observed between the *CDH1* C-160A polymorphism and risk of gastric cancer in all genetic models (AA vs. CC: OR = 1.19, 95%CI: 0.89–1.58; CA vs. CC: OR = 1.01, 95% CI: 0.88–1.15; CA+AA vs. CC: OR = 1.04, 95%CI: 0.91–1.19; AA vs. CC+CA: OR = 1.17, 95%CI: 0.90–1.52) (Fig. 2). There was heterogeneity among the studies ( $P = 0.001$  for the homozygous genetic model;  $P = 0.011$  for the heterozygous genetic model;  $P = 0.001$  for the dominant genetic model;  $P = 0.004$  for the recessive genetic model). To eliminate heterogeneity, we conducted further meta-analyses stratified according to ethnicity, source of controls, quality scores and total sample size. Similarly, in the subgroup analysis stratified by ethnicity, there was no significant association between the *CDH1* C-160A polymorphism and risk of gastric cancer in all genetic models, and so was it in the subgroup analysis stratified by source of controls and quality scores. In the stratified analysis by total sample size, a significant association was observed in the small

sample size subgroup (total sample size < 300) in the homozygous genetic model (OR = 2.24, 95%CI = 1.51–3.34) and recessive genetic model (OR = 2.10, 95%CI = 1.51–3.34) (Table 2).

**Sources of heterogeneity.** There was significant heterogeneity for all genetic model comparison. The study ethnicity, source of controls, quality scores and total sample size were regarded as the potential confounding factors. Metaregression revealed that total sample size was the sources of between-study heterogeneity under homozygous ( $t = -3.00, P = 0.007$ ) and recessive genetic models ( $t = -2.87, P = 0.009$ ), which was consistent with subgroup analyses results in homozygous and recessive genetic models. Moreover, under the dominant genetic model, meta-regression showed that total sample size might be the sources of between-study heterogeneity ( $t = -1.86, P = 0.077$ ), which was also consistent with subgroup analyses results in the dominant genetic model. Simultaneously, we found that the study ethnicity, source of controls, and quality scores did not contribute to the source of heterogeneity.

**Sensitivity analysis.** Some studies with low quality scores (quality scores < 8), or that deviated from Hardy-Weinberg equilibrium (HWE), were enrolled in this meta-analysis. Sensitivity analysis was performed to determine whether these factors had an impact on the overall estimate. The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, respectively. The omission of any single study did not make a significant difference in the pooled effects, suggesting that the results were reliable and stable (Supplementary Figure 1).

**Publication bias.** Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shape of the funnel plot did not reveal any evidence of obvious asymmetry (Fig. 3). Moreover, the Egger's test was used to provide statistical evidence of funnel plot symmetry. The results did not suggest any evidence of publication bias ( $P = 0.323$  for the homozygous genetic model;  $P = 0.131$  for the heterozygous genetic model;  $P = 0.060$  for the dominant genetic model;  $P = 0.497$  for the recessive genetic model).

Table 1 | Characteristics of eligible studies included in the meta-analysis

author	year	country	ethnicity	quality scores	source of controls	sample size (case/control)	HWE	cases			controls		
								CC	CA	AA	CC	CA	AA
Humar <sup>16</sup>	2002	Italy	Caucasian	6	HB	53/70	0.555	17	26	10	40	27	3
Pharoach-C <sup>17</sup>	2002	Canada	Caucasian	8	HB	148/93	0.231	58	76	14	43	44	6
Pharoach-G <sup>17</sup>	2002	Germany	Caucasian	7	HB	132/42	0.345	61	58	13	22	15	5
Pharoach-P <sup>17</sup>	2002	Portugal	Caucasian	7	HB	153/331	0.223	62	80	11	153	151	27
Wu <sup>18</sup>	2002	Taiwan	Asian	9	HB	201/196	0.302	95	102	4	83	94	19
Park <sup>19</sup>	2003	Korea	Asian	5	HB	292/146	0.43	186	92	14	85	55	6
Kuraoka <sup>20</sup>	2003	Japan	Asian	4	HB	106/90	0.01	61	34	11	32	52	6
Shin <sup>21</sup>	2004	Korea	Asian	8	HB	28/142	0.454	21	6	1	110	31	1
Lu <sup>22</sup>	2005	China	Asian	9	PB	206/261	0.391	119	75	12	152	91	18
Song <sup>23</sup>	2005	China	Asian	9	PB	102/101	0.448	58	38	6	55	41	5
Zhang <sup>24</sup>	2005	China	Asian	10	HB	239/343	0.042	170	62	7	228	96	19
Cattaneo <sup>25</sup>	2006	Italy	Caucasian	10	PB	107/246	0.476	50	51	6	139	89	18
Medina-Franco <sup>26</sup>	2007	Mexico	mixed	4	HB	39/78	0.699	15	16	8	44	30	4
Yamada <sup>27</sup>	2007	Japan	Asian	6	HB	148/292	0.919	93	51	4	187	93	12
Jenab <sup>28</sup>	2008	mixed	Caucasian	10	PB	245/949	0.87	119	101	25	451	408	90
Zhang B <sup>29</sup>	2008	China	Asian	8	HB	668/625	0.453	418	211	39	403	194	28
Zhang XF <sup>30</sup>	2008	China	Asian	10	HB	239/343	0.042	170	62	7	228	96	19
Corso <sup>31</sup>	2009	Italy	Caucasian	7	PB	412/408	0.395	206	163	43	185	185	38
Al-Moundhri <sup>32</sup>	2010	Omen	Caucasian	8	PB	174/166	0.429	93	60	21	93	65	8
Borges <sup>33</sup>	2010	Brazil	mixed	6	HB	58/51	0.090	27	20	11	32	14	5
Zhan <sup>34</sup>	2012	China	Asian	10	HB	361/354	0.647	219	116	26	196	137	21
Chu <sup>35</sup>	2014	Taiwan	Asian	10	HB	107/134	0.938	48	44	15	84	44	6

HB, hospital-based; PB, population-based.




Figure 1 | Flow chart of study selection in the meta-analysis.




Figure 2 | Forest plot of the CDHI C-160A polymorphism and risk of gastric cancer under the homozygous genetic model (AA vs. CC).



Table 2 | Pooled ORs and 95% CIs of the association between the CDH1 C-160A polymorphism and risk of gastric cancer

Variable	n°	Sample size (case/control)	AA vs CC			CA/AA vs CC			AA vs CC/CA					
			OR(95%CI)	P <sup>b</sup>	P <sup>c</sup>	OR(95%CI)	P <sup>b</sup>	P <sup>c</sup>	OR(95%CI)	P <sup>b</sup>	P <sup>c</sup>			
overall	22	4218/5461	1.19(0.89-1.58)	0.235	0.001	1.01(0.88-1.15)	0.923	0.011	1.04(0.91-1.19)	0.560	0.001	1.17(0.90-1.52)	0.240	0.004
ethnicity														
Asian	14	2697/3027	0.92(0.61-1.38)	0.681	0.008	0.91(0.77-1.07)	0.246	0.042	0.91(0.77-1.08)	0.278	0.020	0.97(0.65-1.43)	0.862	0.012
Caucasian	8	1424/2305	1.25(0.97-1.61)	0.082	0.106	1.06(0.91-1.23)	0.440	0.062	1.09(0.95-1.26)	0.213	0.053	1.22(0.96-1.56)	0.102	0.149
source														
HB	16	2972/3330	1.23(0.82-1.86)	0.315	0.000	1.03(0.86-1.22)	0.770	0.006	1.07(0.89-1.29)	0.487	0.000	1.19(0.82-1.73)	0.354	0.001
PB	6	1246/2131	1.11(0.85-1.46)	0.431	0.469	0.96(0.82-1.12)	0.572	0.261	0.98(0.85-1.14)	0.835	0.412	1.15(0.89-1.49)	0.293	0.360
quality scores														
≥8	13	2825/3953	1.07(0.73-1.55)	0.737	0.003	0.99(0.89-1.10)	0.882	0.339	1.00(0.90-1.11)	0.973	0.103	1.05(0.74-1.50)	0.779	0.004
<8	9	1393/1508	1.42(0.89-2.25)	0.140	0.044	1.04(0.76-1.42)	0.817	0.001	1.12(0.82-1.53)	0.488	0.001	1.29(0.98-1.71)	0.073	0.123
sample size														
≥300	13	3445/4660	0.95(0.79-1.15)	0.625	0.057	0.95(0.86-1.05)	0.327	0.335	0.95(0.87-1.05)	0.317	0.370	0.93(0.71-1.23)	0.626	0.037
<300	9	773/801	2.24(1.51-3.34)	0.000	0.109	1.19(0.80-1.76)	0.373	0.003	1.34(0.90-2.00)	0.149	0.001	2.10(1.42-3.09)	0.000	0.331

<sup>a</sup>Number of studies

<sup>b</sup>P value of Z test.

<sup>c</sup>P value of Q-test for heterogeneity test.

## Discussion


*CDH1* is recognized as a crucial invasion suppressor gene in several human carcinomas, and inactivation or down regulation of E-cadherin has been found to be correlated with tumor aggressiveness and metastatic potential<sup>36</sup>. A C/A SNP exists at -160 from the transcriptional start site of the *CDH1* gene promoter and the A allele decreases transcriptional efficiency by 68% compared with the C allele *in vitro*<sup>13</sup>, which attracted a lot of attentions to investigate the possible effects of this polymorphism on the susceptibility of gastric cancer. However, results of these studies were not consistent or even contradictory. To resolve this controversy, the present meta-analysis, including 4218 cases and 5461 controls from 22 case-control studies, explored the association between the *CDH1* C-160A polymorphism and risk of gastric cancer.

In the overall data synthesis, there was no association between the *CDH1* C-160A polymorphism and risk of gastric cancer in all genetic models. It was a negative result, but was in accordance with the results of majority studies included in this meta-analysis. Although the single included study showed significant association between certain genotype and susceptibility of gastric cancer, it could not be ruled out the existence of false positive results due to the reasons as follows. First, some studies contained a small sample size, so the results might be not reliable and stable enough. Second, the positive results of some results were contradictory. For example, Wu<sup>18</sup> reported that AA was a protective genotype, while Humar<sup>16</sup> and Chu<sup>35</sup> reported that AA was a susceptible genotype. Due to these inconsistent results, no significant pooled result could be obtained. Meanwhile, sensitivity analysis did not alter the results, implying that the results were robust.

In the stratification analysis of ethnicity, no significant association was observed in any of the genetic models, suggesting that ethnic differences in genetic backgrounds and environmental and social factors did not affect the association between the *CDH1* C-160A polymorphism and risk of gastric cancer. Similar results were observed in the subgroup analysis by source of controls and quality scores. In the subgroup analysis stratified by total sample size, a significant association between the *CDH1* C-160A polymorphism and risk of gastric cancer was observed in the small sample size subgroup in the homozygous genetic model and recessive genetic model. These significant results may be due to the limited sample size of studies, which had insufficient statistical power to support the association and may have generated a fluctuated risk estimate, so the findings in this subgroup should be interpreted with caution.

In order to seek out the genetic variants related to gastric cancer, much effort has been made to explore the association between gene polymorphisms via case-control study. Recently, accumulating number of genome-wide association studies (GWASs) have focused on the association between gene polymorphisms and risk of gastric cancer<sup>37-42</sup>. However, we have not found any data about the association between the *CDH1* C-160A polymorphism and risk of gastric cancer based on GWAS, probably due to some limitations in these studies such as small sample size. Meta-analysis is a powerful method for resolving inconsistent findings from a relatively large number of subjects, so it can obtain more reliable results than a single study. Similarly, we failed to find correlation between the *CDH1* C-160A polymorphism and risk of gastric cancer in this meta-analysis.

Our results indicated that the *CDH1* C-160A polymorphism was not associated with the risk of gastric cancer both in Asian and Caucasian populations, which were in accord with the results of the previous study by Gao<sup>43</sup> and inconsistent with the study by Li<sup>44</sup>. There were two main differences between the prior studies and ours. First, apart from ethnicity, the influence of factors such as study quality and sample size was not stated to explore the potential associations in the subtype analysis. Second, the literature searches of the two previous meta-analyses were conducted before March 2008 and November 2010, respectively. Since then, several



**Figure 3** | Funnel plot for studies of the association of the *CDH1* C-160A polymorphism and risk of gastric under the homozygous genetic model (AA vs. CC).

additional studies of the *CDH1* C-160A polymorphism and risk of gastric cancer were published. Therefore, the sample was larger and the results of our meta-analysis were more reliable than those of previous studies.

All of the studies included in this meta-analysis met our inclusion criteria and the publication bias was not found. In spite of these, several limitations in this analysis should be mentioned when the results are interpreted. First, the meta-analysis was performed at the study level. For lack of sufficient data, we were unable to analyse potential correlative factors such as environmental factors and lifestyle habits which were important in the gastric carcinogenesis. It is also possible that the potential function of this polymorphism is diluted or covered by other genetic background or environment factors, and these important factors should not be ignored. Second, our analysis was limited to Asian and Caucasian populations, therefore, it is unknown whether these results are generalizable to other populations. Third, only published studies were included in this meta-analysis, publication bias might have inevitably occurred. Last, a relatively small number of available studies were included in our meta-analysis, which may reduce the statistical power for identifying possible associations between the *CDH1* C-160A polymorphism and risk of gastric cancer. The findings in this meta-analysis should thus be interpreted with caution.

In conclusion, this meta-analysis failed to confirm the association between the *CDH1* C-160A polymorphism and risk of gastric cancer, indicating that this polymorphism is not a biomarker for susceptibility to gastric cancer. However, large-scale studies in different ethnic groups with more detailed individual data are needed to validate our findings. Investigations of the gene-environment interaction may lead to an improved, more comprehensive understanding of the roles of the *CDH1* C-160A polymorphism in the aetiology of gastric cancer.

## Methods

**Literature search.** Two investigators independently searched eligible studies on the associations between the *CDH1* C-160A polymorphism and gastric cancer. Published studies were identified through a computerized search of PubMed, without language limitation, up to August 2014. Electronic searches were performed by using the following search terms: (*CDH1*, E-cadherin or rs16260) and (gastric cancer, gastric carcinoma or stomach cancer) and polymorphism. In addition, the reference lists of retrieved articles were checked by handsearch for additional potential studies. A study reported results from more than one population was considered as separate studies. Studies included in this meta-analysis had to meet the following inclusion criteria: (a) a case-control study design, (b) evaluated the *CDH1* C-160A polymorphism and risk

of gastric cancer, and (c) had detailed genotype frequency of cases and controls, or frequencies that could be calculated from the article text. Studies deviated from HWE were included and sensitivity analysis was performed to see whether this deviation can have an impact on the overall estimate.

**Data extraction and quality assessment.** Two investigators independently extracted data and reached a consensus on all of the items. The following data were extracted from the eligible studies: the first author's name, year of publication, country, ethnicity, source of controls, evidence of HWE, and numbers of cases and controls. Qualities of studies were assessed according to predefined criteria based on previous observational studies<sup>45,46</sup> (Supplementary Table 1). Study authors were contacted for detailed data when there was insufficient information to determine the relationship between the polymorphism and risk of gastric cancer.

**Statistical analysis.** Pooled ORs and their 95% CIs were used to assess the strength of association between the *CDH1* C-160A polymorphism and risk of gastric cancer. The significance of the pooled ORs was determined by the Z test, and  $P < 0.05$  was considered statistically significant. Homozygous (AA vs. CC), heterozygous (CA vs. CC), dominant (CA+AA vs. CC), and recessive (AA vs. CC+CA) genetic models were investigated. Subgroup analysis was performed by ethnicity, quality scores, source of controls, and total sample size. HWE was tested by the Chi-square test among controls, and  $P < 0.05$  was considered a departure from HWE. Between-study heterogeneity was evaluated by using the Chi-square based Q test. Heterogeneity was considered significant for  $P < 0.05$ , and the random-effects model was used. Otherwise, the fixed-effects model was used. Moreover, a meta-regression was used to delineate the major sources of between-study heterogeneity. Sensitivity analyses were performed to assess the stability of the results. Funnel plots and Egger's linear regression test were used to diagnose potential publication bias, and  $P < 0.05$  was used as an indication for possible publication bias. All analyses were done with Stata software (version 10.0 StataCorp LP, College Station, TX).  $P$  values were two-sided.

- Dicken, B. J. *et al.* Gastric adenocarcinoma: review and considerations for future directions. *Ann Surg.* **241**, 27–39 (2005).
- Nardone, G. Review article: molecular basis of gastric carcinogenesis. *Aliment Pharmacol Ther Suppl.* **2**, 75–81 (2003).
- Takezaki, T. *et al.* Comparative study of lifestyles of residents in high and low risk areas for gastric cancer in Jiangsu Province, China; with special reference to allium vegetables. *J Epidemiol.* **9**, 297–305 (1999).
- Kobayashi, M., Tsubono, Y., Sasazuki, S., Sasaki, S. & Tsugane, S. Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow-up of the JPHC Study Cohort I. *Int J Cancer.* **102**, 39–44 (2002).
- Galanis, D. J., Lee, J. & Kolonel, L. N. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. *Cancer.* **79**, 1840–1841 (1997).
- Zhang, Z. F. *et al.* Helicobacter pylori infection on the risk of stomach cancer and chronic atrophic gastritis. *Cancer Detect Prev.* **23**, 357–367 (1999).
- Setiawan, V. W. *et al.* *GSTT1* and *GSTM1* null genotypes and the risk of gastric cancer: A case-control study in a Chinese population. *Cancer Epidemiol Biomarkers Prev.* **9**, 73–80 (2000).
- Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. *Science.* **251**, 1451–1455 (1991).



9. Takeichi, M. Cadherins: a molecular family important in selective cell-cell adhesion. *Annu Rev Biochem.* **59**, 237–252 (1990).
10. Grunwald, G. B. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol.* **5**, 797–805 (1993).
11. van Roy, F. & Berx, G. The cell-cell adhesion molecule E-cadherin. *Cell Mol Life Sci.* **65**, 3756–3788 (2008).
12. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H. & Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature.* **392**, 190–193 (1998).
13. Li, L. C. *et al.* A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. *Cancer Res.* **60**, 873–876 (2002).
14. Kiemeny, L. A. *et al.* Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. *Eur J Cancer.* **42**, 3219–3227 (2006).
15. Wang, G. Y., Lu, C. Q., Zhang, R. M., Hu, X. H. & Luo, Z. W. The E-cadherin gene polymorphism 160 C → A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. *Am J Epidemiol.* **167**, 7–14 (2008).
16. Humar, B. *et al.* Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. *Oncogene.* **21**, 8192–8195 (2002).
17. Pharoah, P. D. *et al.* CDH1 c-160a promoter polymorphism is not associated with risk of stomach cancer. *Int J Cancer.* **101**, 196–197 (2002).
18. Wu, M. S. *et al.* Association of the -160 C → A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. *Cancer.* **94**, 1443–1448 (2002).
19. Park, W. S. *et al.* A Single Nucleotide Polymorphism in the E-cadherin Gene Promoter -160 is not associated with risk of Korean gastric cancer. *J Korean Med Sci.* **18**, 501–504 (2003).
20. Kuraoka, K. *et al.* Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. *Int J Oncol.* **23**, 421–427 (2003).
21. Shin, Y. *et al.* The E-cadherin-347 G → GA promoter polymorphism and its effect on transcriptional regulation. *Carcinogenesis.* **25**, 895–899 (2004).
22. Lu, Y. *et al.* E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. *World J Gastroenterol.* **11**, 56–60 (2005).
23. Song, C. G. *et al.* Association of -160 (C → A) polymorphism in CDH1 gene with gastric cancer risk in Fujian Chinese population. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* **22**, 557–559 (2005).
24. Zhang, X. F. *et al.* Correlation of E-cadherin polymorphisms to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. *Ai Zheng.* **24**, 513–519 (2005).
25. Cattaneo, F. *et al.* Functional analysis and case-control study of -160 C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. *Anticancer Res.* **26**, 4627–4632 (2006).
26. Medina-Franco, H., Ramos-De la Medina, A., Vizcaino, G. & Medina-Franco, J. L. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. *Ann Surg Oncol.* **14**, 2246–2249 (2007).
27. Yamada, H. *et al.* Association between CDH1 haplotypes and gastric cancer risk in a Japanese population. *Scand J Gastroenterol.* **42**, 1479–1485 (2007).
28. Jenab, M. *et al.* CDH1 gene polymorphisms, smoking, Helicobacter pylori infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Eur J Cancer.* **44**, 774–780 (2008).
29. Zhang, B. *et al.* Genetic polymorphisms of the E-cadherin promoter and risk of sporadic gastric carcinoma in Chinese populations. *Cancer Epidemiol Biomarkers Prev.* **17**, 2402–2408 (2008).
30. Zhang, X. F. *et al.* Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. *Dis Esophagus.* **21**, 21–29 (2008).
31. Corso, G. *et al.* CDH1 C-160A promoter polymorphism and gastric cancer risk. *Eur J Cancer Prev.* **18**, 46–49 (2009).
32. Al-Moundhri, M. S. *et al.* Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. *World J Gastroenterol.* **16**, 3432–3436 (2010).
33. Borges Bdo, N. *et al.* Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. *Anticancer Res.* **30**, 2225–2233 (2010).
34. Zhan, Z. *et al.* CDH1 gene polymorphisms, plasma CDH1 levels and risk of gastric cancer in a Chinese population. *Mol Biol Rep.* **39**, 8107–8113 (2012).
35. Chu, C. M. *et al.* CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case-control study based on direct sequencing analysis. *World J Surg Oncol.* **12**, 80 (2014).
36. Christofori, G. & Semb, H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends Biochem Sci.* **24**, 73–76 (1999).
37. Abnet, C. C. *et al.* A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. *Nat Genet.* **42**, 764–767 (2010).
38. Wang, L. D. *et al.* Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. *Nat Genet.* **42**, 759–763 (2010).
39. Shi, Y. *et al.* A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. *Nat Genet.* **43**, 1215–1218 (2011).
40. Jin, G. *et al.* Genetic variants at 6p21.1 and 7p15.3 are associated with risk of multiple cancers in Han Chinese. *Am J Hum Genet.* **91**, 928–934 (2012).
41. Saeki, N., Ono, H., Sakamoto, H. & Yoshida, T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. *Cancer Sci.* **104**, 1–8 (2013).
42. Saeki, N., Sakamoto, H. & Yoshida, T. Mucin 1 gene (MUC1) and gastric-cancer susceptibility. *Int J Mol Sci.* **15**, 7958–7973 (2014).
43. Gao, L., Nieters, A. & Brenner, H. Meta-analysis: tumour invasion-related genetic polymorphisms and gastric cancer susceptibility. *Aliment Pharmacol Ther.* **28**, 565–573 (2008).
44. Li, Y. L., Tian, Z., Zhang, J. B. & Fu, B. Y. CDH1 promoter polymorphism and stomach cancer susceptibility. *Mol Biol Rep.* **39**, 1283–1286 (2012).
45. Zheng, R. L., Zhang, H. & Jiang, W. L. Tumor necrosis factor-alpha 308G. A polymorphism and risk of rheumatic heart disease: a meta-analysis. *Sci Rep.* **4**, 4731 (2014).
46. Thakkinstian, A., D'Este, C., Eisman, J., Nguyen, T. & Attia, J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. *J Bone Miner Res.* **19**, 419–428 (2004).

## Author contributions

B.J. and K.Z. conceived and designed the experiments. H.S. and C.B. performed the experiments. K.Z., J.O. and W.S. analyzed the data. B.J. wrote the paper.

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Jiang, B. *et al.* Lack of association between the CDH1 polymorphism and gastric cancer susceptibility: a meta-analysis. *Sci. Rep.* **5**, 7891; DOI:10.1038/srep07891 (2015).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>